Walgreens Shareholders Approve $10 Billion Private Equity Buyout
Walgreens Boots Alliance shareholders have given their approval to private equity firm Sycamore Partners’ $10 billion buyout offer for the iconic drugstore chain. The deal, which was first announced in March, will see Sycamore Partners paying $11.45 per share, a 29% premium above the December stock price for Walgreens. Additionally, Sycamore will have the opportunity to receive up to $3 in cash per Walgreens share from the future monetization of WBA’s debt and equity interests in VillageMD, which includes the Village Medical, Summit Health, and CityMD businesses.
The shareholder vote, which took place at a special meeting, saw about 96% of votes cast in favor of the merger agreement proposal. Walgreens CEO Tim Wentworth expressed appreciation for the overwhelming support from shareholders, stating that the partnership with Sycamore will help accelerate their turnaround strategy and enhance the customer, patient, and team member experience.
The transaction is expected to close in the third or fourth quarter of this year, pending customary closing conditions and regulatory approvals. This deal comes after Walgreens faced financial challenges due to a failed in-store clinic rollout and the closure of hundreds of stores to reduce debt. Under former CEO Roz Brewer, Walgreens invested billions in physician-staffed clinic operator VillageMD but has since scaled back on clinic expansion.
Despite the setbacks, Wentworth remains optimistic about the future of Walgreens under Sycamore’s ownership. The company aims to become the top choice for pharmacy, retail, and health services, with a focus on improving the overall customer experience. Stay tuned for more updates on this exciting development in the coming months.
